Sunpointe LLC Takes $288,000 Position in Danaher Corporation $DHR

Key Points

• Sunpointe LLC acquired 1,454 shares of Danaher Corporation valued at approximately $288,000 in the second quarter.
• Analysts have set a consensus target price of $246.35 for Danaher stock, with ratings currently reflecting a "Moderate Buy" sentiment.
• Danaher announced a quarterly dividend of $0.32 per share, representing an annualized yield of 0.7% and a payout ratio of 27.23%.

Sunpointe LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,454 shares of the conglomerate's stock, valued at approximately $288,000.

Other hedge funds have also recently made changes to their positions in the company. Bank Pictet & Cie Europe AG raised its position in shares of Danaher by 22.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after acquiring an additional 35,730 shares during the last quarter. Waverly Advisors LLC increased its holdings in Danaher by 24.8% in the fourth quarter. Waverly Advisors LLC now owns 10,596 shares of the conglomerate's stock worth $2,432,000 after purchasing an additional 2,109 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new stake in Danaher in the fourth quarter worth approximately $1,993,000. Voloridge Investment Management LLC bought a new stake in Danaher in the fourth quarter worth approximately $3,763,000. Finally, Delta Investment Management LLC bought a new stake in Danaher in the fourth quarter worth approximately $211,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of NYSE:DHR traded up $2.32 during midday trading on Thursday, reaching $195.26. 2,871,387 shares of the company traded hands, compared to its average volume of 3,258,148. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The firm has a market capitalization of $139.82 billion, a price-to-earnings ratio of 41.55, a price-to-earnings-growth ratio of 2.69 and a beta of 0.75. The firm's fifty day moving average price is $200.40 and its two-hundred day moving average price is $198.47.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DHR. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Deutsche Bank Aktiengesellschaft reduced their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Finally, Guggenheim reissued a "buy" rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.